Interpace Diag Group (IDXG)

$1.71 -0.18 (-9.68%)
Market Cap 8.36M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 26,500
Avg Vol 13,892
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 4%
Beta 1.05
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Buster67
Buster67 Jan. 30 at 3:56 PM
$IDXG No pressure advantage
0 · Reply
Esau815
Esau815 Jan. 28 at 2:14 PM
$IDXG Prior to uplisting IDXG would need some sort of a deal announced. With 84% concentrated in the 2 PE firms and 5% to a 3rd sharehodler, I doubt that the remaining 11% is spread to the requisite amount of shareholders. Dates to be aware of March 31 and May 15. Annual report is relased on March 31 and Q1 on May 15. Don't think that they would announce any deal prior to the annual report and audit. But before May 15? That would be likely IMHO in that they would be reporting how much cash they have on hand and without debt? It could be substantial.
1 · Reply
giulipano
giulipano Jan. 26 at 6:47 PM
$IDXG
0 · Reply
Cujo
Cujo Jan. 25 at 4:47 PM
$IDXG Uplisting requires sustained bid price above $4.X, minimum shareholders' equity, and market maker support, which IDXG is addressing through balance sheet cleanup (now debt-free). Past delays and microcap volatility could push it beyond early 2026; investors should watch SEC filings for Form 10-Q/10-K updates or formal applications
0 · Reply
Esau815
Esau815 Jan. 25 at 1:19 PM
$IDXG There's zero chance that this company remains status quo. With the preferred finally converting to common there must be a reason. Either the company gets sold or it makes an acquisition by issuing additional stock. The two PE firms own 84% and another major holder has 5%. This is a different company now that revenues have stabilized to pre PancraGen levels and even more importantly debt free.
0 · Reply
jimbo8711
jimbo8711 Jan. 20 at 3:17 PM
$IDXG time to avg down
0 · Reply
Esau815
Esau815 Jan. 20 at 2:36 PM
$IDXG It's readily apparent that someone thinks something is going on. Not surprising. If this were a private company or part of a bigger company another $3MM in annual cost savings on top of the $6MM debt burden expenses gone on top of the $250K per month FCF. That's about $10MM FCF at a minimum. Put an 8 handle on that? That's about $3 per share.
1 · Reply
Esau815
Esau815 Jan. 14 at 4:39 PM
$IDXG Does somebody know something that nobody else knows (including me). There's a 25K bid at $1.25. I haven't seen a bid like that in ages.
1 · Reply
Esau815
Esau815 Jan. 11 at 3:11 AM
$IDXG Question. Now that the debt has been paid? What are they going to do with that $500K per month FCF? Any chance they can buy back stock?
0 · Reply
Waters59
Waters59 Dec. 23 at 2:15 PM
$IDXG Let's Go! 📈
0 · Reply
Latest News on IDXG
No data available.
Buster67
Buster67 Jan. 30 at 3:56 PM
$IDXG No pressure advantage
0 · Reply
Esau815
Esau815 Jan. 28 at 2:14 PM
$IDXG Prior to uplisting IDXG would need some sort of a deal announced. With 84% concentrated in the 2 PE firms and 5% to a 3rd sharehodler, I doubt that the remaining 11% is spread to the requisite amount of shareholders. Dates to be aware of March 31 and May 15. Annual report is relased on March 31 and Q1 on May 15. Don't think that they would announce any deal prior to the annual report and audit. But before May 15? That would be likely IMHO in that they would be reporting how much cash they have on hand and without debt? It could be substantial.
1 · Reply
giulipano
giulipano Jan. 26 at 6:47 PM
$IDXG
0 · Reply
Cujo
Cujo Jan. 25 at 4:47 PM
$IDXG Uplisting requires sustained bid price above $4.X, minimum shareholders' equity, and market maker support, which IDXG is addressing through balance sheet cleanup (now debt-free). Past delays and microcap volatility could push it beyond early 2026; investors should watch SEC filings for Form 10-Q/10-K updates or formal applications
0 · Reply
Esau815
Esau815 Jan. 25 at 1:19 PM
$IDXG There's zero chance that this company remains status quo. With the preferred finally converting to common there must be a reason. Either the company gets sold or it makes an acquisition by issuing additional stock. The two PE firms own 84% and another major holder has 5%. This is a different company now that revenues have stabilized to pre PancraGen levels and even more importantly debt free.
0 · Reply
jimbo8711
jimbo8711 Jan. 20 at 3:17 PM
$IDXG time to avg down
0 · Reply
Esau815
Esau815 Jan. 20 at 2:36 PM
$IDXG It's readily apparent that someone thinks something is going on. Not surprising. If this were a private company or part of a bigger company another $3MM in annual cost savings on top of the $6MM debt burden expenses gone on top of the $250K per month FCF. That's about $10MM FCF at a minimum. Put an 8 handle on that? That's about $3 per share.
1 · Reply
Esau815
Esau815 Jan. 14 at 4:39 PM
$IDXG Does somebody know something that nobody else knows (including me). There's a 25K bid at $1.25. I haven't seen a bid like that in ages.
1 · Reply
Esau815
Esau815 Jan. 11 at 3:11 AM
$IDXG Question. Now that the debt has been paid? What are they going to do with that $500K per month FCF? Any chance they can buy back stock?
0 · Reply
Waters59
Waters59 Dec. 23 at 2:15 PM
$IDXG Let's Go! 📈
0 · Reply
Waters59
Waters59 Dec. 19 at 3:25 PM
$IDXG Let's Rock & Roll!!
1 · Reply
Esau815
Esau815 Dec. 11 at 3:48 AM
$IDXG Reminder to those unfamiliar with IDXG's cap table. Though the PE Preferred shareholders gave up their preference in 2024, they still can convert to 23MM shares--there are really 27MM shares outstanding. Not 4MM. In terms of valuation based on FCF or EBITDA. Ten times EBITDA gets you a MC of $50MM but ten times cash flow is $70MM or so now that the debt is paid. That gets you $2-$3 per share. You can't get to $20 per share with 27MM shares oustanding under any fantasy scenario.
0 · Reply
doylebery
doylebery Dec. 10 at 5:11 PM
$IDXG
0 · Reply
davidb1010
davidb1010 Dec. 10 at 2:18 AM
$IDXG $IDXG My average price still $17 1.2k shares 😂
1 · Reply
Gojilla24
Gojilla24 Dec. 9 at 11:45 PM
$IDXG nice to see this finally showing some signs of life.
0 · Reply
Esau815
Esau815 Dec. 9 at 12:44 AM
$IDXG WIth all due respect to Waters. There is no way no how that this valuation goes anywhere close to $8. Think you have overlooked that the preferred shares are 81% of the cap table and that the 4MM shares are the 19%. There are 27MM diluted shares outstanding--not 4MM. To have an $8 shares you would need a market cap north of $200MM. Realistically? Even at 10 EBITDA (very generous) you would need EBITDA of $20MM. Maybe if we had PancraGen and still had original reimbursement for thyroid we'd get close. But we're at $5MM EBITDA.
2 · Reply
Esau815
Esau815 Dec. 8 at 4:22 PM
$IDXG First of all--want to shout from the rooftops that I don't have any material non public information. But it's sure trading like someone knows that a deal is imminent. 25k shares on IDXG? That's a millisecond volume in AAPL but an enormous amount for IDXG. There's no shares to be found. Let's see if they get that $2 share price.
1 · Reply
Esau815
Esau815 Dec. 7 at 12:34 AM
$IDXG Think we can get to a sales price of $2.00 a share which is what the preferred shares gave up their preference. (When the stock was $2.85.) REMEMBER. CAUTION. There are 27MM shares outstanding--not 4MM. The preferred gave up their preference but still will get 23MM shares or so when they convert. With the demise of PancraGen it's a bit tricky to figure out what thyroid alone does. It appears that they ma $911 k in Q3. Know you can't extapolate that to cash flow but let's say it's in the ball park. Now. Add $500K per month committed to principal and interest payments. Let's add a bit of growth and I think you can get to close to $1MM per month. 27MM shares. Need $54MM market cap. Figure roughly $12MM FCF. 4.5 times FCF seems to me a reasonable multiple. Even tiny diagnostics get 6. They might need a quarter or two as a "show me stock"
0 · Reply
Esau815
Esau815 Dec. 6 at 12:32 PM
$IDXG Let's give credit to a strong management team that was dealt some very bad cards out of their control. That $12MM debt coupled with the (then) imminent demise of PancraGen would have killed many a company. Their fight of the reimbursement caused about a 2 year delay which lasted long enough to pare down 80% of the debt and they were able to eke out the last 20% by the skin of their teeth. A debt free IDXG will now generate about $500K in FCF. Hopefully, this will be sufficient for the two PE's who own 81% of the company to find a suitable suitor. Ten times cash flow would equate to a little north of $2 per share. This happened to be the price at which they converted. Think that all involved would like to move on.
1 · Reply
Zapp
Zapp Dec. 4 at 1:22 AM
$IDXG great news re: early payoff of 2021 BroadOak debt. Time for a 🚀
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG 2/2 With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG PARSIPPANY, NJ , Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021 , with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest expenses, providing increased operational flexibility to support future growth. “The early repayment of the BroadOak facility is a significant milestone for Interpace and a testament to our robust financial performance and disciplined capital management,” said Chris McCarthy , Chief Financial Officer. “Over the past several years, BroadOak has been a valuable partner, supporting our strategic turnaround and transition to profitability.
0 · Reply